Advertisement

International Journal of Clinical Oncology

, Volume 24, Issue 12, pp 1629–1631 | Cite as

Considering bone health in the treatment of prostate cancer bone metastasis based on the results of the ERA-223 trial

  • Atsushi MizokamiEmail author
  • Go Kimura
  • Yasuhisa Fujii
  • Shiro Hinotsu
  • Kouji Izumi
Letter to the Editor
  • 159 Downloads

ERA-223, a phase III clinical trial, was conducted globally to investigate the usefulness of radium-223 (Ra-223) administered concurrently with abiraterone acetate and prednisolone (AAP) [1]. However, in this trial, the Ra-223 + AAP group did not exhibit increased survival and had a clearly higher incidence of bone fracture than the placebo + AAP group. In this paper, we would like to discuss the reasons why this study did not produce the anticipated outcomes, and how we should use Ra-223 in consideration of both efficacy and bone health.

Testosterone and its metabolic estrogen maintain bone health by preventing loss of bone mineral density. When serum estrogen decreases, the frequency of fracture rises [ 2]. Androgen-deprivation therapy (ADT) also induces loss of bone mineral density and muscle strength, leading to frailty and consequently increased frequency of fractures [ 3]. However, the antitumor effect of ADT outweighs its adverse effect on bone health, and for this reason it is...

Notes

Compliance with ethical standards

Conflict of interest

No author has any conflict of interest.

References

  1. 1.
    Smith M, Parker C, Saad F et al (2019) Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:408–419CrossRefGoogle Scholar
  2. 2.
    Vandenput L, Ohlsson C (2009) Estrogens as regulators of bone health in men. Nat Rev Endocrinol 5(8):437–443CrossRefGoogle Scholar
  3. 3.
    Hyde Z, Flicker L, Almeida OP et al (2010) Low free testosterone predicts frailty in older men: the health in men study. J Clin Endocrinol Metabol 95:3165–3172CrossRefGoogle Scholar
  4. 4.
    Logothetis CJ, Basch E, Molina A et al (2012) Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 13:1210–1217CrossRefGoogle Scholar
  5. 5.
    Suominen MI, Fagerlund KM, Rissanen JP et al (2017) Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models. Clin Cancer Res 23:4335–4346CrossRefGoogle Scholar
  6. 6.
    Tombal BF, Loriot Y, Sasd F et al (2019) Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis. J Clin Oncol 37(15_suppl):5007CrossRefGoogle Scholar
  7. 7.
    Izumi K, Kadono Y, Shima T et al (2010) Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients. Anticancer Res 30:5201–5205PubMedGoogle Scholar
  8. 8.
    Sciarra A, Gentile V, Cattarino S et al (2015) Oral ethinylestradiol in castration-resistant prostate cancer: a 10-year experience. Int J Urol 22:98–103CrossRefGoogle Scholar
  9. 9.
    Langley RE, Kynaston HG, Alhasso AA, et al. A randomised comparison evaluating changes in bone mineral density in advanced prostate cancer: luteinising hormone-releasing hormone agonists versus transdermal oestradiol. Eur Urol 69:1016–1025.CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  • Atsushi Mizokami
    • 1
    Email author
  • Go Kimura
    • 2
  • Yasuhisa Fujii
    • 3
  • Shiro Hinotsu
    • 4
  • Kouji Izumi
    • 1
  1. 1.Department of UrologyKanazawa UniversityKanazawaJapan
  2. 2.Department of UrologyNippon Medical SchoolTokyoJapan
  3. 3.Department of UrologyTokyo Medical and Dental UniversityTokyoJapan
  4. 4.Department of Biostatistics and Clinical EpidemiologySapporo Medical UniversitySapporoJapan

Personalised recommendations